Safety and pharmacokinetics of escalating daily doses of the antituberculosis drug rifapentine in healthy volunteers

K. E. Dooley, E. E. Bliven-Sizemore, M. Weiner, Y. Lu, E. L. Nuermberger, W. C. Hubbard, E. J. Fuchs, M. T. Melia, W. J. Burman, S. E. Dorman

Research output: Contribution to journalArticlepeer-review

Abstract

Rifapentine (RPT) is an antituberculosis drug that may shorten treatment duration when substituted for rifampin (RIF). The maximal tolerated daily dose of RPT and its potential for cytochrome 3A4 induction and autoinduction at clinically relevant doses are unknown. In this phase I, dose-escalation study among healthy volunteers, daily doses as high as a prespecified maximum of 20 mg/kg/day were well tolerated. Steady-state RPT concentrations increased with dose from 5 to 15 mg/kg, but area under the plasma concentration-time curve (AUC 0-24) and maximum concentration (C max) were similar in the 15- and 20-mg/kg cohorts. Although RPT pharmacokinetics (PK) appeared to be time-dependent, accumulation occurred with daily dosing. The mean AUC 0-12 of oral midazolam (MDZ), a cytochrome 3A (CYP3A) probe drug, was reduced by 93% with the coadministration of RPT and by 74% with the coadministration of RIF (P < 0.01). Changes in the oral clearance of MDZ did not vary by RPT dose. In conclusion, RPT was tolerated at doses as high as 20 mg/kg/day, its PK were less than dose-proportional, and its CYP3A induction was robust.

Original languageEnglish (US)
Pages (from-to)881-888
Number of pages8
JournalClinical pharmacology and therapeutics
Volume91
Issue number5
DOIs
StatePublished - May 2012

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Safety and pharmacokinetics of escalating daily doses of the antituberculosis drug rifapentine in healthy volunteers'. Together they form a unique fingerprint.

Cite this